02:44
Precision BioSciences Reports Second Quarter 2024 Financial Results & Provides Business Update!
04:39
The burdens of Hepatitis B with Dr. Jordan Feld
33:16
Investing in Impact: Targeting HBV with Gene Editing Precision
06:35
ARCUS In Vivo Gene Editing for Chronic Hepatitis B Virus
26:24
Precision BioSciences' ARCUS Genome Editing Technology
02:14
We are Precision BioSciences
02:09:43
Precision BioSciences In Vivo Gene Editing R&D Event Webcast Recording
01:55
Precision BioSciences: Culture
01:43
Precision BioSciences: Benefits
01:35
Precision BioSciences: Passion for the Mission
01:38
Precision BioSciences: Professional Development
01:39
Precision BioSciences: Science Spotlight
01:51
Precision BioSciences: Growth of the Business
04:01
CAR T Explained by Precision BioSciences
05:01
DEDICATED: The Origins Of Precision BioSciences
X
About
Precision BioSciences (Nasdaq: DTIL) is a clinical stage gene editing company Dedicated to Improving Life. We are advancing the development of ARCUS®-based ex vivo allogeneic CAR T therapies for hematologic malignancies and in vivo gene editing therapies for genetic diseases. ARCUS is a highly precise and versatile genome editing platform designed for therapeutic safety, delivery and control.
Tags